知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.017 秒)

    USE OF FOLATES FOR PRODUCING A PREPARATION SUITABLE FOR PREVENTING AND TREATING INFLAMMATION AND DISEASES ASSOCIATED WITH INFLAMMATION, ESPECIALLY FOR INFLUENCING THE INFLAMMATION MARKERS CRP AND SAA
    1.
    发明申请
    USE OF FOLATES FOR PRODUCING A PREPARATION SUITABLE FOR PREVENTING AND TREATING INFLAMMATION AND DISEASES ASSOCIATED WITH INFLAMMATION, ESPECIALLY FOR INFLUENCING THE INFLAMMATION MARKERS CRP AND SAA 审中-公开
    用于生产适用于预防和治疗与炎症相关的炎症和疾病的制剂的专门用途，特别是用于影响炎症标志物CRP和SAA

    公开(公告)号：US20100179095A1

    公开(公告)日：2010-07-15

    申请号：US12696660

    申请日：2010-01-29

    申请人： Thomas MUELLER ,  Rudolf Moser ,  Martin Ulmann

    发明人： Thomas MUELLER ,  Rudolf Moser ,  Martin Ulmann

    IPC分类号： A61K38/22 ,  A61K31/4985 ,  A61K31/525 ,  A61K31/7056 ,  A61K31/675 ,  A61K31/19 ,  A61P25/28 ,  A61P19/02 ,  A61P11/08 ,  A61P35/00 ,  A61P29/00

    CPC分类号： A61K45/06 ,  A61K31/375 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/714 ,  A61K2300/00

    摘要： This invention relates to the use of folates for producing a pharmaceutical preparation suitable for the prevention and treatment of inflammation and of diseases associated with inflammation, particularly for influencing the inflammation markers C-reactive protein (CRP) and serum amyloid A protein (SAA). The clinical areas of application are all anomalies of the CRP and SAA levels.The invention also relates to pharmaceutical preparations for the prevention and treatment of inflammation and of diseases associated with inflammation, particularly for influencing CRP and SAA levels, characterised in that as an active ingredient it comprises at least one compound which is selected from the group consisting of pteroic acid monoglutamate (folic acid), dihydrofolic acid, 5-formyltetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, 5,10-methenyl-tetrahydrofolic acid, 10-formyltetrahydrofolic acid or tetrahydrofolic acid, polyglutamates thereof, optical isomers thereof, particularly optically pure natural isomers thereof, and mixtures of optical isomers also, particularly racemic mixtures, as well as pharmaceutically acceptable salts thereof also, together with pharmaceutically acceptable active ingredients and adjuvants.

    摘要翻译： 本发明涉及叶酸用于制备适于预防和治疗炎症及与炎症有关的疾病的药物制剂的用途，特别是用于影响炎症标记物C反应蛋白（CRP）和血清淀粉样蛋白A蛋白（SAA）。 临床应用领域都是CRP和SAA水平的异常。 本发明还涉及用于预防和治疗炎症和与炎症有关的疾病的药物制剂，特别是用于影响CRP和SAA水平，其特征在于作为活性成分，其包含至少一种选自以下的化合物： 戊酸单谷氨酸（叶酸），二氢叶酸，5-甲酰四氢叶酸，5-甲基四氢叶酸，5,10-亚甲基四氢叶酸，5,10-甲基四氢叶酸，10-甲酰四氢叶酸或四氢叶酸，聚谷氨酸，旋光异构体 ，特别是光学纯的天然异构体，以及光学异构体的混合物，特别是外消旋混合物，以及其药学上可接受的盐，以及药学上可接受的活性成分和佐剂。

    Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa
    2.
    发明申请
    Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa 审中-公开
    使用叶酸来制备适合于预防和治疗与炎症有关的炎症和疾病的制剂，特别是用于影响炎症标记物crp和saa

    公开(公告)号：US20060063768A1

    公开(公告)日：2006-03-23

    申请号：US10505777

    申请日：2003-02-24

    申请人： Thomas Mueller ,  Rudolf Moser ,  Martin Ulmann

    发明人： Thomas Mueller ,  Rudolf Moser ,  Martin Ulmann

    IPC分类号： A61K31/525

    CPC分类号： A61K45/06 ,  A61K31/375 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/714 ,  A61K2300/00

    摘要： This invention relates to the use of folates for producing a pharmaceutical preparation suitable for the prevention and treatment of inflammation and of diseases associated with inflammation, particularly for influencing the inflammation markers C-reactive protein (CRP) and serum amyloid A protein (SAA). The clinical areas of application are all anomalies of the CRP and SM levels. The invention also relates to pharmaceutical preparations for the prevention and treatment of inflammation and of diseases associated with inflammation, particularly for influencing CRP and SM levels, characterised in that as an active ingredient it comprises at least one compound which is selected from the group consisting of pteroic acid monoglutamate (folic acid), dihydrofolic acid, 5-formyltetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, 5,10-methenyl-tetrahydrofolic acid, 10-formyltetrahydrofolic acid or tetrahydrofolic acid, polyglutamates thereof, optical isomers thereof, particularly optically pure natural isomers thereof, and mixtures of optical isomers also, particularly racemic mixtures, as well as pharmaceutically acceptable salts thereof also, together with pharmaceutically acceptable active ingredients and adjuvants.

    摘要翻译： 本发明涉及叶酸用于制备适于预防和治疗炎症及与炎症有关的疾病的药物制剂的用途，特别是用于影响炎症标记物C反应蛋白（CRP）和血清淀粉样蛋白A蛋白（SAA）。 临床应用领域都是CRP和SM水平的异常。 本发明还涉及用于预防和治疗炎症以及与炎症有关的疾病，特别是用于影响CRP和SM水平的药物制剂，其特征在于作为活性成分，其包含至少一种选自以下的化合物： 戊酸单谷氨酸（叶酸），二氢叶酸，5-甲酰四氢叶酸，5-甲基四氢叶酸，5,10-亚甲基四氢叶酸，5,10-甲基四氢叶酸，10-甲酰四氢叶酸或四氢叶酸，聚谷氨酸，旋光异构体 ，特别是光学纯的天然异构体，以及光学异构体的混合物，特别是外消旋混合物，以及其药学上可接受的盐，以及药学上可接受的活性成分和佐剂。

    Sodium salt of (6S)-folinic acid
    6.
    发明授权
    Sodium salt of (6S)-folinic acid 失效
    （6S） - 醋酸的钠盐

    公开(公告)号：US6160116A

    公开(公告)日：2000-12-12

    申请号：US459692

    申请日：1995-06-02

    申请人： Hans Rudolf Mueller ,  Martin Ulmann ,  Josef Conti ,  Gunter Muerdel

    发明人： Hans Rudolf Mueller ,  Martin Ulmann ,  Josef Conti ,  Gunter Muerdel

    IPC分类号： C07D475/04

    CPC分类号： C07D475/04

    摘要： The invention relates to a process for preparing (6S)-folinic acid and its salts by recrystallization of alkaline-earth salts of (6R,S)-folinic acid and, where necessary, liberation of the acid from the alkaline-earth folinates and/or, where necessary, conversion into the alkali salts by at least one recrystallization in the presence of a base. The invention also relates to calcium-, magnesium-, potassium- and sodium-(6S)-folinates and to (6S)-folinic acid prepared in accordance with the invention.

    摘要翻译： 本发明涉及一种通过（6R，S） - 赖氨酸的碱土金属盐的重结晶和必要时从碱土金属叶酸和/或碱土金属盐释放酸来制备（6S） - 丝氨酸及其盐的方法， 或者如果需要，在碱的存在下通过至少一次重结晶转化成碱金属盐。 本发明还涉及根据本发明制备的钙，镁，钾和钠 - （6S） - 叶酸和（6S） - 丝氨酸。

    Use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level, particularly for assisting the remethylation of homocysteine
    7.
    发明授权
    Use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level, particularly for assisting the remethylation of homocysteine 失效
    使用天然立体异构体形式的四氢叶酸盐可用于制备适于影响同型半胱氨酸水平的药物制剂，特别是用于辅助同型半胱氨酸的再甲基化

    公开(公告)号：US6011040A

    公开(公告)日：2000-01-04

    申请号：US95572

    申请日：1998-06-11

    申请人： Hans Rudolf Muller ,  Martin Ulmann ,  Rudolf Moser

    发明人： Hans Rudolf Muller ,  Martin Ulmann ,  Rudolf Moser

    IPC分类号： C07D475/04 ,  A61K31/4415 ,  A61K31/505 ,  A61K31/519 ,  A61K31/555 ,  A61P7/00 ,  A61P9/00 ,  A61P43/00

    CPC分类号： A61K31/519

    摘要： This invention relates to the use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level, particularly for assisting the remethylation of homocysteine. Clinical areas of application include all anomalies of the homocysteine level, particularly the prevention and treatment of cardiovascular diseases and the prevention of neural tube deficiencies. The present invention also relates to pharmaceutical preparations comprising at least one compound selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetra-hydrofolic acid or (6S)-tetrahydrofolic acid or pharmaceutically compatible salts thereof, together with pharmaceutically compatible active and adjuvant substances, for influencing the homocysteine level, particularly when a methylene tetrahydrofolate reductase deficiency exists, such as when thermolabile methylene tetrahydrofolate reductase exists for example.

    摘要翻译： 本发明涉及以天然立体异构形式的四氢叶酸在制备适于影响同型半胱氨酸水平的药物制剂中的用途，特别是用于辅助同型半胱氨酸的再次乙基化。 临床应用领域包括同型半胱氨酸水平的所有异常，特别是预防和治疗心血管疾病和预防神经管缺陷。 本发明还涉及包含至少一种选自5-甲酰基 - （6S） - 四氢叶酸，5-甲基 - （6S） - 四氢叶酸，5,10-亚甲基 - （6R） - 四氢叶酸， （6R） - 四氢叶酸，5-甲酰基 - （6R） - 四氢叶酸，5-甲酰基 - （6S） - 四氢叶酸或（6S） - 四氢叶酸或药学上相容的 其盐与药学上相容的活性和佐剂物质一起用于影响同型半胱氨酸水平，特别是当存在亚甲基四氢叶酸还原酶缺陷时，例如当存在不可耐受的亚甲基四氢叶酸还原酶时。

    Stable crystalline (6S)- and (6R)-tetrahydrofolic acid
    8.
    发明授权
    Stable crystalline (6S)- and (6R)-tetrahydrofolic acid 失效
    稳定的结晶（6S） - 和（6R） - 四氢叶酸

    公开(公告)号：US06271374B1

    公开(公告)日：2001-08-07

    申请号：US09013266

    申请日：1998-01-26

    申请人： Hans Rudolf Müller ,  Martin Ulmann ,  Rudolf Moser ,  Thomas Ammann

    发明人： Hans Rudolf Müller ,  Martin Ulmann ,  Rudolf Moser ,  Thomas Ammann

    IPC分类号： C07D47504

    CPC分类号： C07D475/04

    摘要： Pure and extremely stable crystalline (6S)- and (6R)-tetrahydrofolic acids, absolutely inert even when exposed to air and elevated temperature without stabilizers being added, are prepared by a crystallization process at a pH of ≧3.5 for the preparation of crystalline (6S)-tetrahydrofolic acid and at a pH of ≧2 for the preparation of crystalline (6R)-tetrahydrofolic acid.

    摘要翻译： 纯度和非常稳定的结晶（6S） - 和（6R） - 四氢叶酸，即使暴露于空气和高温下也绝对是惰性的，没有添加稳定剂，通过结晶过程制备pH> 3.5，用于制备结晶 （6S） - 四氢叶酸，pH> = 2，用于制备结晶（6R） - 四氢叶酸。

    Pharmaceutical compositions containing (65)-folinic acid and salts thereof
    10.
    发明授权
    Pharmaceutical compositions containing (65)-folinic acid and salts thereof 失效
    含有（65） - 叶酸及其盐的药物组合物

    公开(公告)号：US5347005A

    公开(公告)日：1994-09-13

    申请号：US896482

    申请日：1992-06-02

    申请人： Hans R. Mueller ,  Martin Ulmann ,  Josef Conti ,  Gunter Muerdel

    发明人： Hans R. Mueller ,  Martin Ulmann ,  Josef Conti ,  Gunter Muerdel

    IPC分类号： C07D475/04

    CPC分类号： C07D475/04

    摘要： The invention relates to a process for preparing (6S)-folinic acid and its salts by recrystallization of alkaline-earth salts of (6R,S)-folinic acid and, where necessary, liberation of the acid from the alkaline-earth folinates and/or, where necessary, conversion into the alkali salts by at least one recrystallization in the presence of a base.The invention also relates to calcium-, magnesium-, potassium- and sodium-(6S)-folinates and to (6S)-folinic acid prepared in accordance with the invention.

    摘要翻译： 本发明涉及一种通过（6R，S） - 赖氨酸的碱土金属盐的重结晶和必要时从碱土金属叶酸和/或碱土金属盐释放酸来制备（6S） - 丝氨酸及其盐的方法， 或者如果需要，在碱的存在下通过至少一次重结晶转化成碱金属盐。 本发明还涉及根据本发明制备的钙，镁，钾和钠 - （6S） - 叶酸和（6S） - 丝氨酸。